

**OMOP 2011 Symposium - January 11, 2011
Renaissance Washington, DC Dupont Circle Hotel
1143 New Hampshire Avenue, Washington, DC.**

AGENDA

9:00 a.m. -10:30 a.m.

1. Welcome

Thomas P. Scarnecchia, MS, Executive Director OMOP

2. Review of the OMOP Experiment

Marc Overhage, MD, PhD, Director, Medical Informatics and Research Scientist, Regenstrief Institute, Inc., Regenstrief Professor of Medical Informatics, Indiana University School of Medicine
CEO and President Indiana Health Information Exchange; OMOP Research Investigator

3. Method Performance Results from the Health Outcomes of Interest Experiment

Patrick Ryan, MEng, Associate Director, Analytical Epidemiology, Johnson & Johnson Pharmaceutical Research and Development, OMOP Research Investigator

David Madigan, PhD, Professor, Columbia University, OMOP Research Investigator

10:30 a.m. -10:45 a.m.

BREAK

10: 45 a.m. – 12:15 p.m.

4. Method Performance Results from the Health Outcomes of Interest Experiment (continued)

12:15 p.m. -1:00 p.m.

LUNCH (Provided)

1:00 p.m. – 1:30 p.m.

5. Panel Discussion: Method Performance Results from the Health Outcomes of Interest Experiment

Paul Stang, PhD, Senior Director, Epidemiology, Johnson & Johnson Pharmaceutical Research and Development, OMOP Research Investigator

Shawn Murphy MD, PhD, Medical Director of Research Computing and Informatics, Partners Healthcare Research Computing; Assistant Professor, Harvard Medical School

Niklas Norén, PhD, Manager, Research Department, Uppsala Monitoring Centre
WHO Collaborating Centre for International Drug Monitoring

Ram Tiwari, PhD, Associate Director, Office of Biostatistics, CDER/FDA

Judy A. Staffa, PhD, R.Ph., FDA/CDER/OSE, Associate Director for Regulatory Research

1:30 p.m. -3:00 p.m.

6. Lessons Learned from Systematic Observational Analysis

Short Presentations

Standardized Tools for Data Characterization and Utility of Exploratory Visualization

Paul Stang, PhD, Senior Director, Epidemiology, Johnson & Johnson Pharmaceutical Research and Development, OMOP Research Investigator

Managing Data Quality for an Active Surveillance System

Christian Reich, MD, PhD, Program Director OMOP

Implications of Health Outcomes of Interest Definitions – Acute Liver Injury Case Study

Judith A. Racoosin, MD, MPH, Sentinel Initiative Scientific Lead, FDA; OMOP Research Investigator

Post Presentations - Panel Discussion

Marc Overhage, MD, PhD, Director, Medical Informatics and Research Scientist, Regenstrief Institute, Inc.; Regenstrief Professor of Medical Informatics, Indiana University School of Medicine
CEO and President Indiana Health Information Exchange; OMOP Research Investigator

Joshua S. Benner, Pharm.D., Sc.D. Research Director, Engelberg Center for Health Care Reform, Brookings Institution.

Abraham G. Hartzema PharmD, MSPH, PhD, FISPE, Professor and Eminent Scholar, Perry A. Foote Chair in Health Outcomes and Pharmacoeconomics; Professor, Department of Epidemiology and Biostatistics, College of Public Health and Health Professions, University of Florida; OMOP Research Investigator

William D. Marder, PhD, Senior Vice President and General Manager, Healthcare & Science Thomson Reuters

Richard Platt, MD, MSc, Professor and Chair of the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care

Mitra Rocca, Associate Director, Medical Informatics, FDA

3:00 p.m. – 3:15 p.m. BREAK

3:15 p.m. - 4:00 p.m.

7. Future Research and Applications Beyond Drug Safety Signal Refinement

Opportunities for Signal Detection in an Active Surveillance System

Andrew Bate, PhD, Pfizer Inc., Senior Director, Analytics Team Lead, Epidemiology, Worldwide Safety Strategy

OMOP Methods Application for Comparative Effectiveness

Jesse Berlin, ScD, Johnson & Johnson Pharmaceutical R & D, Vice President, Epidemiology

OMOP's Future

Thomas P. Scarnecchia, MS, Executive Director OMOP

4:00 p.m. – 4:30 p.m.

8. Summary - How OMOP Informs the National Effort

Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, Food and Drug Administration; Chair, Observational Medical Outcomes Partnership Executive Board

4:30 p.m. – 5:00 p.m.

9. Open Q/A with the OMOP Research Investigators